| Ident. | Authors (with country if any) | Title |
|---|
| 000002 |
Magda Osman [Royaume-Uni] ; Agata Rytersk [Royaume-Uni] ; Kash Karimi [Royaume-Uni] ; LINGLING TU [République populaire de Chine] ; Ignacio Obeso [Canada] ; Maarten Speekenbrink [Royaume-Uni] ; Marjan Jahanshahi [Royaume-Uni] | The effects of dopaminergic medication on dynamic decision making in Parkinson's disease |
| 000003 |
Stéphanie Bissonnette [Canada] ; Sophie Muratot [Canada] ; Nathalie Vernoux [Canada] ; François Bezeau [Canada] ; Frédéric Calon [Canada] ; Sébastien S. Hebert [Canada] ; Pershia Samadi [Canada] | The effect of striatal pre-enkephalin overexpression in the basal ganglia of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease |
| 000024 |
Claudine Habak [Canada] ; Anne Noreau [Canada] ; Atsuko Nagano-Saito [Canada] ; Beatriz Mejia-Constain [Canada] ; Clotilde Degroot [Canada] ; Antonio P. Strafella [Canada] ; Sylvain Chouinard [Canada] ; Anne-Louise Lafontaine [Canada] ; Guy A. Rouleau [Canada] ; Oury Monchi [Canada] | Dopamine transporter SLC6A3 genotype affects cortico-striatal activity of set-shifts in Parkinson's disease |
| 000028 |
D. Ouazia [Canada] ; L.-C. Jr Levros [Canada] ; E. Rassart [Canada] ; R. R. Desrosiers [Canada] | DOPAMINE DOWN-REGULATION OF PROTEIN L-ISOASPARTYL METHYLTRANSFERASE IS DEPENDENT ON REACTIVE OXYGEN SPECIES IN SH-SY5Y CELLS |
| 000029 |
Leigh Christopher [Canada] ; Connie Marras [Canada] ; Sarah Duff-Canning [Canada] ; Yuko Koshimori [Canada] ; Robert Chen [Canada] ; Isabelle Boileau [Canada] ; Barbara Segura [Canada, Espagne] ; Oury Monchi [Canada] ; Anthony E. Lang [Canada] ; Pablo Rusjan [Canada] ; Sylvain Houle [Canada] ; Antonio P. Strafella [Canada] | Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment |
| 000033 |
Mauro Pettorruso [Italie] ; Giovanni Martinotti [Italie] ; Alfonso Fasano [Canada] ; Giovanna Loria [Italie] ; Marco Di Nicola [Italie] ; Luisa De Risio [Italie] ; Lucia Ricciardi [Italie] ; Gianluigi Conte [Italie] ; Luigi Janiri [Italie] ; Anna Rita Bentivoglio [Italie] | Anhedonia in Parkinson's disease patients with and without pathological gambling: A case-control study |
| 000059 |
JI HYUN KO [Canada] ; Francesca Antonelli [Canada] ; Oury Monchi [Canada] ; Nicola Ray [Canada] ; Pablo Rusjan [Canada] ; Sylvain Houle [Canada] ; Anthony E. Lang [Canada] ; Leigh Christopher [Canada] ; Antonio P. Strafella [Canada] | Prefrontal Dopaminergic Receptor Abnormalities and Executive Functions in Parkinson's Disease |
| 000071 |
Philip Seeman [Canada] ; Michele Tinazzi [Italie] | Loss of dopamine neuron terminals in antipsychotic-treated schizophrenia; relation to tardive dyskinesia |
| 000074 |
David Mongeon [Canada] ; Pierre Blanchet [Canada] ; Julie Messier [Canada] | Impact of Parkinson's disease and dopaminergic medication on adaptation to explicit and implicit visuomotor perturbations |
| 000085 |
Kaylena A. Ehgoetz Martens [Canada] ; Colin G. Ellard [Canada] ; Quincy J. Almeida [Canada] | Dopaminergic contributions to distance estimation in Parkinson's disease: A sensory-perceptual deficit? |
| 000093 |
Edward Stein [Israël] ; Izhar Bar-Gad [Israël] | Beta oscillations in the cortico-basal ganglia loop during parkinsonism |
| 000101 |
Dominic Nadeau [Canada] ; Isabelle Giroux [Canada] ; Julie Dufour [Canada] ; Martine Simard [Canada] | Jeu pathologique chez les patients atteints de la maladie de Parkinson |
| 000115 |
D. Domenger [Canada] ; D. Dea [Canada] ; L. Theroux [Canada] ; L. Moquin [Canada] ; A. Gratton [Canada] ; J. Poirier [Canada] | The MPTP neurotoxic lesion model of Parkinson's disease activates the apolipoprotein E cascade in the mouse brain |
| 000120 |
Sébastien Helie [États-Unis] ; Erick J. Paul [États-Unis] ; F. Gregory Ashby [États-Unis] | Simulating the effects of dopamine imbalance on cognition: From positive affect to Parkinson's disease |
| 000141 |
John S. Yeomans [Canada] | Muscarinic Receptors in Brain Stem and Mesopontine Cholinergic Arousal Functions |
| 000148 |
Russell C. Callaghan [Canada] ; James K. Cunningham [États-Unis] ; Jenna Sykes [Canada] ; Stephen J. Kish [Canada] | Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs |
| 000176 |
Julia Sacher [Canada, Allemagne] ; Eugenii A. Rabiner [Canada] ; Michael Clark [Canada] ; Pablo Rusjan [Canada] ; Alexandra Soliman [Canada] ; Rada Boskovic [Canada] ; Stephen J. Kish [Canada] ; Alan A. Wilson [Canada] ; Sylvain Houle [Canada] ; Jeffrey H. Meyer [Canada] | Dynamic, adaptive changes in MAO-A binding after alterations in substrate availability: an in vivo [11C]-harmine positron emission tomography study |
| 000177 |
Bernard Ravina [États-Unis] ; Kenneth Marek [États-Unis] ; Shirley Eberly [États-Unis] ; David Oakes [États-Unis] ; Roger Kurlan [États-Unis] ; Alberto Ascherio [États-Unis] ; Flint Beal [États-Unis] ; James Beck [États-Unis] ; Emily Flagg [États-Unis] ; Wendy R. Galpern [États-Unis] ; Jennifer Harman [États-Unis] ; Anthony E. Lang [Canada] ; Michael Schwarzschild [États-Unis] ; Caroline Tanner [États-Unis] ; Ira Shoulson [États-Unis] | Dopamine Transporter Imaging Is Associated With Long-Term Outcomes in Parkinson's Disease |
| 000178 |
Aimee J. Nelson [Canada] ; Azra Premji [Canada] ; Navjot Rai [Canada] ; Tasnuva Hoque [Canada] ; Mark Tommerdahl [États-Unis] ; Robert Chen [Canada] | Dopamine Alters Tactile Perception in Parkinson's Disease |
| 000215 |
Penny A. Macdonald [Canada] ; Alex A. Macdonald [Canada] ; Ken N. Seergobin [Canada] ; Ruzbeh Tamjeedi [Canada] ; Hooman Ganjavi [Canada] ; Jean-Sebastien Provost [Canada] ; Oury Monchi [Canada] | The effect of dopamine therapy on ventral and dorsal striatum-mediated cognition in Parkinson's disease: support from functional MRI |
| 000254 |
A. Jon Stoessl [Canada] ; David J. Brooks [Royaume-Uni] ; David Eidelberg [États-Unis] | Milestones in Neuroimaging |
| 000257 |
Ramachandiran Nandhagopal [Canada] ; Lisa Kuramoto [Canada] ; Michael Schulzer [Canada] ; Edwin Mak [Canada] ; Jacqueline Cragg [Canada] ; Jess Mckenzie [Canada] ; Siobhan Mccormick [Canada] ; Thomas J. Ruth [Canada] ; Vesna Sossi [Canada] ; Raul De La Fuente-Fernandez [Canada] ; A. Jon Stoessl [Canada] | Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease |
| 000259 |
Francesca Antonelli [Canada] ; Nicola Ray [Canada] ; Antonio P. Strafella [Canada] | Impulsivity and Parkinson's disease: More than just disinhibition |
| 000262 |
Andrew R. Brown [Canada] ; Michael C. Antle [Canada] ; BIN HU [Canada] ; G. Campbell Teskey [Canada] | High frequency stimulation of the subthalamic nucleus acutely rescues motor deficits and neocortical movement representations following 6-hydroxydopamine administration in rats |
| 000271 |
Anne M. Landau [Danemark, Canada] ; M. Mallar Chakravarty [Danemark, Canada] ; Campbell M. Clark [Canada] ; Athanasios P. Zis [Canada] ; Doris J. Doudet [Danemark, Canada] | Electroconvulsive Therapy Alters Dopamine Signaling in the Striatum of Non-human Primates |
| 000276 |
Alexander Klein [Canada] ; Darryl C. Gidyk [Canada] ; Alexandra M. Shriner [Canada] ; Keri L. Colwell [Canada] ; Nadine A. Tatton [Canada] ; William G. Tatton [Canada] ; Gerlinde A. Metz [Canada] | Dose-dependent loss of motor function after unilateral medial forebrain bundle rotenone lesion in rats: A cautionary note |
| 000282 |
Jacqueline A. Gleave [Canada] ; Troy H. Farncombe [Canada] ; Chantal Saab [Canada] ; Laurie C. Doering [Canada] | Correlative single photon emission computed tomography imaging of [123I]altropane binding in the rat model of Parkinson's |
| 000297 |
Moran Weinberger [Canada] ; Jonathan O. Dostrovsky [Canada] | A basis for the pathological oscillations in basal ganglia: the crucial role of dopamine |
| 000300 |
Joseph K. Eibl [Canada] ; Zouleika Abdallah [Canada] ; Gregory M. Ross [Canada] | Zinc-metallothionein: a potential mediator of antioxidant defence mechanisms in response to dopamine-induced stress |
| 000304 |
Sandra E. Leh [Canada] ; Michael Petrides [Canada] ; Antonio P. Strafella [Canada] | The Neural Circuitry of Executive Functions in Healthy Subjects and Parkinson's Disease |
| 000360 |
Sarah C. Lidstone [Canada] ; Michael Schulzer [Canada] ; Katherine Dinelle [Canada] ; Edwin Mak [Canada] ; Vesna Sossi [Canada] ; Thomas J. Ruth [Canada] ; Raul De La Fuente-Fernandez [Canada] ; Anthony G. Phillips [Canada] ; A. Jon Stoessl [Canada] | Effects of Expectation on Placebo-Induced Dopamine Release in Parkinson Disease |
| 000368 |
Vesna Sossi [Canada] ; Raul De La Fuente-Fernandez [Canada] ; Ramachandiran Nandhagopal [Canada] ; Michael Schulzer [Canada] ; Jessamyn Mckenzie [Canada] ; Thomas J. Ruth [Canada] ; Jan O. Aasly [Norvège] ; Matthew J. Farrer [États-Unis] ; Zbigniew K. Wszolek [États-Unis] ; Jon A. Stoessl [Canada] | Dopamine Turnover Increases in Asymptomatic LRRK2 Mutations Carriers |
| 000383 |
B. Xu [Canada] ; J. S. Goldman [Canada] ; V. V. Rymar [Canada] ; C. Forget [Canada] ; P. S. Lo [Canada] ; S. J. Bull [Canada] ; E. Vereker [Canada] ; P. A. Barker [Canada] ; L. E. Trudeau [Canada] ; A. F. Sadikot [Canada] ; T. E. Kennedy [Canada] | CRITICAL ROLES FOR THE NETRIN RECEPTOR DELETED IN COLORECTAL CANCER IN DOPAMINERGIC NEURONAL PRECURSOR MIGRATION, AXON GUIDANCE, AND AXON ARBORIZATION |
| 000403 |
Alexander Klein [Canada, Allemagne] ; Johanna Wessolleck [Allemagne] ; Anna Papazoglou [Allemagne] ; Gerlinde A. Metz [Canada] ; Guido Nikkhah [Allemagne] | Walking pattern analysis after unilateral 6-OHDA lesion and transplantation of foetal dopaminergic progenitor cells in rats |
| 000404 |
Desirae M. Haluk [Canada] ; Stan B. Floresco [Canada] | Ventral Striatal Dopamine Modulation of Different Forms of Behavioral Flexibility |
| 000405 |
Daniel Weintraub [États-Unis] ; Staci Hoops [États-Unis] ; Judy A. Shea [États-Unis] ; Kelly E. Lyons [États-Unis] ; Rajesh Pahwa [États-Unis] ; Erika D. Driver-Dunckley [États-Unis] ; Charles H. Adler [États-Unis] ; Marc N. Potenza [États-Unis] ; Janis Miyasaki [Canada] ; Andrew D. Siderowf [États-Unis] ; John E. Duda [États-Unis] ; Howard I. Hurtig [États-Unis] ; Amy Colcher [États-Unis] ; Stacy S. Horn [États-Unis] ; Matthew B. Stern [États-Unis] ; Valerie Voon [États-Unis] | Validation of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease |
| 000426 |
A. R. Troiano [Canada] ; R. De La Fuente-Fernandez [Canada] ; V. Sossi [Canada] ; M. Schulzer [Canada] ; E. Mak [Canada] ; T. J. Ruth [Canada] ; A. J. Stoessl [Canada] | PET demonstrates reduced dopamine transporter expression in PD with dyskinesias |
| 000430 |
Andrew R. Brown [Canada] ; BIN HU [Canada] ; Michael C. Antle [Canada] ; G. Campbell Teskey [Canada] | Neocortical movement representations are reduced and reorganized following bilateral intrastriatal 6-hydroxydopamine infusion and dopamine type-2 receptor antagonism |
| 000432 |
Pierre-Luc Tremblay [Canada] ; Marc-Andre Bedard [Canada] ; Maxime Levesque [Canada] ; Mark Chebli [Canada] ; Maxime Parent [Canada] ; Richard Courtemanche [Canada] ; Pierre J. Blanchet [Canada] | Motor sequence learning in primate : Role of the D2 receptor in movement chunking during consolidation |
| 000438 |
Jonathan Brotchie [Canada] ; Cheryl Fitzer-Attas [Israël] | Mechanisms compensating for dopamine loss in early Parkinson disease |
| 000453 |
Emily N. Mangano [Canada] ; Shawn Hayley [Canada] | Inflammatory priming of the substantia nigra influences the impact of later paraquat exposure: Neuroimmune sensitization of neurodegeneration |
| 000454 |
T. D. L. Steeves [Canada] ; J. Miyasaki [Canada] ; M. Zurowski [Canada] ; A. E. Lang [Canada] ; G. Pellecchia [Canada] ; T. Van Eimeren [Canada] ; P. Rusjan [Canada] ; S. Houle [Canada] ; A. P. Strafella [Canada] | Increased striatal dopamine release in Parkinsonian patients with pathological gambling : a [11C] raclopride PET study |
| 000455 |
Andrew H. Evans [Australie] ; Antonio P. Strafella [Canada] ; Daniel Weintraub [États-Unis] ; Mark Stacy [États-Unis] | Impulsive and Compulsive Behaviors in Parkinson's Disease |
| 000460 |
D. Mongeon [Canada] ; P. Blanchet [Canada] ; J. Messier [Canada] | IMPACT OF PARKINSON'S DISEASE AND DOPAMINERGIC MEDICATION ON PROPRIOCEPTIVE PROCESSING |
| 000469 |
Stuart W. S. Macdonald [Canada, Suède] ; Simon Cervenka [Suède] ; Lars Farde [Suède] ; Lars Nyberg [Suède] ; Lars B Ckman [Suède] | Extrastriatal dopamine D2 receptor binding modulates intraindividual variability in episodic recognition and executive functioning |
| 000473 |
R. J. Grant [Canada] ; L. H. L. Sellings [Canada] ; S. J. Crocker [États-Unis] ; E. Melloni [Italie] ; D. S. Park [Canada] ; P. B. S. Clarke [Canada] | EFFECTS OF CALPAIN INHIBITION ON DOPAMINERGIC MARKERS AND MOTOR FUNCTION FOLLOWING INTRASTRIATAL 6-HYDROXYDOPAMINE ADMINISTRATION IN RATS |
| 000476 |
Jennifer R. St. Onge [Canada] ; Stan B. Floresco [Canada] | Dopaminergic Modulation of Risk-Based Decision Making |
| 000477 |
Abdoul Kane [Canada] ; William D. Hutchison [États-Unis, Canada] ; Mojgan Hodaie [États-Unis, Canada] ; Andres M. Lozano [États-Unis, Canada] ; Jonathan O. Dostrovsky [États-Unis, Canada] | Dopamine-dependent high-frequency oscillatory activity in thalamus and subthalamic nucleus of patients with Parkinson's disease |
| 000478 |
Vesna Sossi [Canada] ; Katherine Dinelle [Canada] ; Geoffrey J. Topping [Canada] ; James E. Holden [États-Unis] ; Doris Doudet [Canada] ; Michael Schulzer [Canada] ; Thomas J. Ruth [Canada] ; A. Jon Stoessl [Canada] ; Raul De La Fuente-Femandez [Canada] | Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's : an in vivo imaging study |
| 000479 |
Atsuko Nagano-Saito [Canada] ; JIAQIANG LIU [Canada] ; Julien Doyon [Canada] ; Alain Dagher [Canada] | Dopamine modulates default mode network deactivation in elderly individuals during the Tower of London task |
| 000492 |
N. M. Jadavji [Canada] ; G. A. Metz [Canada] | BOTH PRE-AND POST-LESION EXPERIENTIAL THERAPY IS BENEFICIAL IN 6-HYDROXYDOPAMINE DOPAMINE-DEPLETED FEMALE RATS |
| 000505 |
Patrick Fitzgerald [Irlande (pays)] ; Arkady Mandel [Canada] ; Anthony E. Bolton [Irlande (pays)] ; Aideen M. Sullivan [Irlande (pays)] ; Yvonne Nolan [Irlande (pays)] | Treatment with phosphotidylglycerol-based nanoparticles prevents motor deficits induced by proteasome inhibition : Implications for Parkinson's disease |
| 000542 |
Jesse Jackson [Canada] ; Calvin K. Young [Canada] ; BIN HU [Canada] ; Brian H. Bland [Canada] | High frequency stimulation of the posterior hypothalamic nucleus restores movement and reinstates hippocampal-striatal theta coherence following haloperidol-induced catalepsy |
| 000544 |
A. H. Rajput [Canada] ; H. H. Sitte [Autriche] ; A. Rajput [Canada] ; M. E. Fenton [Canada] ; C. Pifl [Autriche] ; O. Hornykiewicz [Autriche] | Globus pallidus dopamine and Parkinson motor subtypes : Clinical and brain biochemical correlation |
| 000546 |
Frank J. S. Lee [Canada] ; FANG LIU [Canada] | Genetic factors involved in the pathogenesis of Parkinson's disease |
| 000576 |
S. Potvin [Canada] ; S. Grignon [Canada] | Dopamine et douleur : une revue de littérature : Fibromyalgie |
| 000586 |
Philippe Huot [Canada] ; Martin Levesque [Canada] ; André Parent [Canada] | The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea |
| 000589 |
Brigitte Stemmer [Canada] ; Sidney J. Segalowitz [Canada] ; Jane Dywan [Canada] ; Michel Panisset [Canada] ; Calvin Melmed [Canada] | The error negativity in nonmedicated and medicated patients with Parkinson's disease |
| 000590 |
Matthew J. Lavoie [États-Unis] ; Giuseppe P. Cortese [États-Unis] ; Beth L. Ostaszewski [États-Unis] ; Michael G. Schlossmacher [Canada] | The effects of oxidative stress on parkin and other E3 ligases |
| 000591 |
Moigan Hodaie [Canada] ; Joseph S. Neimat [États-Unis] ; Andres M. Lozano [Canada] ; Erik C. Parker ; Patrick J. Kelly ; Philip A. Starr ; Julie G. Pilitsis ; Roy A. E. Bakay | The dopaminergic nigrostriatal system and Parkinson's disease : Molecular events in development, disease, and cell death, and new therapeutic strategies. Commentary |
| 000594 |
Mélanie Bourque [Canada] ; BIN LIU [États-Unis] ; Dean E. Dluzen [États-Unis] ; Therese Di Paolo [Canada] | Tamoxifen protects male mice nigrostriatal dopamine against methamphetamine-induced toxicity |
| 000595 |
Brian N. Mathur [États-Unis] ; M. Diana Neely [États-Unis] ; Melanie Dyllick-Brenzinger [Canada] ; Anurag Tandon [Canada] ; Ariel Y. Deutch [États-Unis] | Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration |
| 000596 |
Brian N. Mathur [États-Unis] ; M. Diana Neely [États-Unis] ; Melanie Dyllick-Brenzinger [Canada] ; Anurag Tandon [Canada] ; Ariel Y. Deutch [États-Unis] | Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration |
| 000611 |
Michelle R. Ciucci [États-Unis] ; Sean T. Ma [États-Unis] ; Cynthia Fox [États-Unis] ; Jacqueline R. Kane [États-Unis] ; Lorraine O. Ramig [États-Unis] ; Timothy Schallert [États-Unis] | Qualitative changes in ultrasonic vocalization in rats after unilateral dopamine depletion or haloperidol : A preliminary study |
| 000613 |
YU YAO [Canada] ; Amandio Vieira [Canada] | Protective activities of Vacciniutn antioxidants with potential relevance to mitochondrial dysfunction and neurotoxicity |
| 000615 |
XUPING LI [République populaire de Chine] ; DEHUA YANG [République populaire de Chine] ; LIANG LI [République populaire de Chine] ; CHANGGENG PENG [République populaire de Chine] ; SHEN CHEN [République populaire de Chine] ; WEIDONG LE [République populaire de Chine] | Proteasome inhibitor lactacystin disturbs the intracellular calcium homeostasis of dopamine neurons in ventral mesencephalic cultures |
| 000621 |
Daniel Levesque [Canada] ; Claude Rouillard [Canada] | Nur77 and retinoid X receptors : crucial factors in dopamine-related neuroadaptation |
| 000632 |
Jessica M. Castellano [Canada] ; Jody Batrynchuk [Canada] ; Kristine Dolbeare [États-Unis] ; Vaneeta Verma [Canada] ; Amandeep Mann [Canada] ; Kevin J. Skoblenick [Canada] ; Rodney L. Johnson [États-Unis] ; Ram K. Mishra [Canada] | MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats |
| 000633 |
Jessica M. Castellano [Canada] ; Jody Batrynchuk [Canada] ; Kristine Dolbeare [États-Unis] ; Vaneeta Verma [Canada] ; Amandeep Mann [Canada] ; Kevin J. Skoblenick [Canada] ; Rodney L. Johnson [États-Unis] ; Ram K. Mishra [Canada] | MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats |
| 000654 |
Philippe Huot [Canada] ; André Parent [Canada] | Dopaminergic neurons intrinsic to the striatum |
| 000656 |
M. Berk [Australie] ; S. Dodd [Australie] ; M. Kauer-Sant'Anna [Canada] ; G. S. Malhi [Australie] ; M. Bourin [France] ; F. Kapczinski [Brésil] ; T. Norman [Australie] | Dopamine dysregulation syndrome : implications for a dopamine hypothesis of bipolar disorder |
| 000658 |
Vesna Sossi [Canada] ; Raul De La Fuente-Fernandez [Espagne] ; Michael Schulzer [Canada] ; Andre R. Troiano [Canada] ; Thomas J. Ruth [Canada] ; A. Jon Stoessl [Canada] | Dopamine Transporter Relation to Dopamine Turnover in Parkinson's Disease : A Positron Emission Tomography Study |
| 000660 |
L. Borgal [Canada] ; M. Hong [Canada] ; D. Sadi [Canada] ; I. Mendez [Canada] | Differential effects of glial cell line-derived neurotrophic factor on A9 and A10 dopamine neuron survival in vitro |
| 000690 |
Martine Saint-Pierre [Canada] ; Marie-Eve Tremblay [Canada] ; Attila Sik [Canada] ; Robert E. Gross [États-Unis] ; Francesca Cicchetti [Canada] | Temporal effects of paraquat/maneb on microglial activation and dopamine neuronal loss in older rats |
| 000694 |
Pepijn Van Den Munckhof [Canada] ; Francois Gilbert [Canada] ; Michel Chamberland [Canada] ; Daniel Levesque [Canada] ; Jacques Drouin [Canada] | Striatal neuroadaptation and rescue of locomotor deficit by L-dopa in aphakia mice, a model of parkinson's disease |
| 000711 |
Claire Ardouin [France] ; Valerie Voon [Canada] ; Yulia Worbe [France] ; Nehman Abouazar [France] ; Virginie Czernecki [France] ; Hassan Hosseini [France] ; Antoine Pelissolo [France] ; Elena Moro [Canada] ; Eugénie Lhommee [France] ; Anthony E. Lang [Canada] ; Yves Agid [France] ; Alim-Louis Benabid [France] ; Pierre Pollak [France] ; Luc Mallet [France] ; Paul Krack [France] | Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation |
| 000712 |
Kaveh M. Koochesfahani [Canada] ; Raul De La Fuente-Fernandez [Canada, Espagne] ; Vesna Sossi [Canada] ; Michael Schulzer [Canada] ; Lakshmi N. Yatham [Canada] ; Thomas J. Ruth [Canada] ; Stephan Blinder [Canada] ; A. Jon Stoessl [Canada] | Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients : Positron emission tomographic studies |
| 000718 |
JUNCHAO TONG [Canada] ; Oleh Hornykiewicz [Autriche] ; Stephen J. Kish [Canada] | Inverse relationship between brain noradrenaline level and dopamine loss in parkinson disease : A possible neuroprotective role for noradrenaline |
| 000731 |
N. M. Jadavji [Canada] ; B. Kolb [Canada] ; G. A. Metz [Canada] | Enriched environment improves motor function in intact and unilateral dopamine-depleted rats |
| 000757 |
Naomi P. Visanji [Canada] ; Mark J. Millan [France] ; Jonathan M. Brotchie [Canada] | Actions at sites other than D3 receptors mediate the effects of BP897 on L-DOPA-induced hyperactivity in monoamine-depleted rats |
| 000762 |
R. A. Bressan [Brésil] ; J. A. Crippa [Brésil] | The role of dopamine in reward and pleasure behaviour : review of data from preclinical research |
| 000815 |
Deniz Kirik [Suède] ; Anders Björklund [Suède] ; Ivar Mendez [Canada] ; Rosario Sanchez-Pernaute [États-Unis] ; Oliver Cooper [États-Unis] ; Angel Vinuela [États-Unis] ; Daniela Ferrari [États-Unis] ; Lars Björklund [États-Unis] ; Alain Dagher [Canada] ; Ole Isacson [États-Unis] | Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Commentary |
| 000824 |
GUOWEI HUANG [Canada, République populaire de Chine] ; Magdalena Dragan [Canada] ; David Freeman [Canada] ; John X. Wilson [Canada, États-Unis] | Activation of catechol-O-methyltransferase in astrocytes stimulates homocysteine synthesis and export to neurons |
| 000834 |
L. Clark [Royaume-Uni] ; R. Cools [Royaume-Uni] ; T. W. Robbins [Royaume-Uni] | The neuropsychology of ventral prefrontal cortex: Decision-making and reversal learning |
| 000839 |
Christopher J. Macdonald [États-Unis] ; Warren H. Meck [États-Unis] | Systems-level integration of interval timing and reaction time |
| 000847 |
M. A. Silverdale [Royaume-Uni] ; S. L. Nicholson [Royaume-Uni] ; P. Ravenscroft [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; M. J. Millan [France] ; J. M. Brotchie [Canada] | Selective blockade of D3 dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate |
| 000850 |
Howard T. J. Mount [Canada] ; Jean-Claude Martel [France] ; Paul Fluit [Canada] ; YINGJI WU [Canada] ; Eleanor Gallo-Hendrikx [Canada] ; Cristina Cosi [France] ; Marc R. Marien [France] | Progressive sensorimotor impairment is not associated with reduced dopamine and high energy phosphate donors in a model of ataxia-telangiectasia |
| 000852 |
Raul De La Fuente-Fernandez [Canada, Espagne] ; Michael Schulzer [Canada] ; Edwin Mak [Canada] ; Donald B. Calne [Canada] ; A. Jon Stoessl [Canada] | Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model |
| 000858 |
Raul De La Fuente-Fernandez [Canada, Espagne] ; Michael Schulzer [Canada] ; A. Jon Stoessl [Canada] | Placebo mechanisms and reward circuitry: Clues from Parkinson's disease |
| 000868 |
Raul De La Fuente-Fernandez [Canada] ; Vesna Sossi [Canada] ; ZHIGAO HUANG [Canada] ; Sarah Furtado [Canada] ; Jian-Qiang Lu [Canada] ; Donald B. Calne [Canada] ; Thomas J. Ruth [Canada] ; A. Jon Stoessl [Canada] | Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias |
| 000873 |
Frédéric Calon [Canada] ; Mehdi Dridi [Canada] ; Oleh Hornykiewicz [Canada, Autriche] ; Paul J. Bedard [Canada] ; Ali H. Rajput [Canada] ; Thérèse Di Paolo [Canada] | Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias |
| 000884 |
Naila Ismayilova [Canada] ; Alan Crossman [Canada] ; Alexei Verkhratsky [Canada] ; Jonathan Brotchie [Canada] | Effects of adenosine A1, dopamine D1 and metabotropic glutamate 5 receptors-modulating agents on locomotion of the reserpinised rats |
| 000886 |
Gregory Dalbo [Canada] ; Fannie St-Gelais [Canada] ; Marc Danik [Canada] ; Sylvain Williams [Canada] ; Mathieu Cotton [Canada] ; Louis-Eric Trudeau [Canada] | Dopamine neurons in culture express VGLUT2 explaining their capacity to release glutamate at synapses in addition to dopamine |
| 000893 |
Vesna Sossi [Canada] ; Raul De La Fuente-Fernandez [Canada] ; James E. Holden [Canada] ; Michael Schulzer [Canada] ; Thomas J. Ruth [États-Unis] ; Jon Stoessl [Canada] | Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: Their relation to disease-compensatory mechanisms |
| 000896 |
Junchao Tong [Canada] ; Paul S. Fitzmaurice [Canada] ; Lee Cyn Ang [Royaume-Uni] ; Yoshiaki Furukawa [Canada] ; Mark Gunman [Canada] ; Stephen J. Kish [Canada] | Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy |
| 000903 |
Ajit Kumar [Canada] ; Sharanpal Mann [Canada] ; Vesna Sossi [Canada] ; Thomas J. Ruth [Canada] ; A. Jon Stoessl [Canada] ; Michael Schulzer [Canada] ; Chong S. Lee [Canada] | [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease |
| 000913 |
Antonio P. Strafella [Canada] ; Abbas F. Sadikot [Canada] ; Alain Dagher [Canada] | Subthalamic deep brain stimulation does not induce striatal dopamine release in Parkinson's disease |
| 000914 |
Antonio P. Strafella [Canada] ; Tomas Paus [Canada] ; Maria Fraraccio [Canada] ; Alain Dagher [Canada] | Striatal dopamine release induced by repetitive transcranial magnetic stimulation of the human motor cortex |
| 000915 |
Aviva Abosch [Canada] ; Shitij Kapur [Canada] ; Anthony E. Lang [Canada] ; Doug Hussey [Canada] ; Elspeth Sime [Canada] ; Janis Miyasaki [Canada] ; Svlvain Houle [Canada] ; Andres M. Lozano [Canada] ; Philip Starr ; Giovanni Broggi ; Roy A. E. Bakay ; Nicholas Boulis ; Ali R. Rezai | Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release. Commentary |
| 000917 |
Alan L. Whone [Royaume-Uni] ; Ray L. Watts [États-Unis] ; A. Jon Stoessl [Canada] ; Margaret Davis [États-Unis] ; Sven Reske [Allemagne] ; Claude Nahmias [Canada] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Maria J. Ribeiro [France] ; Philippe Remy [France] ; Werner Poewe [Autriche] ; Robert A. Hauser [États-Unis] ; David J. Brooks [Royaume-Uni] | Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study |
| 000925 |
Erwan Bezard [France] ; Christian E. Gross [France] ; Jonathan M. Brotchie [Canada] | Presymptomatic compensation in Parkinson's disease is not dopamine-mediated |
| 000933 |
Pershia Samadi [Canada] ; Laurent Gregoire [Canada] ; Paul J. Bedard [Canada] | Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems |
| 000943 |
Larissa Takser [France] ; Donna Mergler [Canada] ; Georgette Hellier [France] ; Josiane Sahuquillo [France] ; Guy Huel [France] | Manganese, monoamine metabolite levels at birth, and child psychomotor development |
| 000958 |
V. Sossi [Canada] ; J. E. Holden [États-Unis] ; R. De La Fuente-Fernandez [Canada] ; T. J. Ruth [Canada] ; A. J. Stoessl [Canada] | Effect of dopamine loss and the metabolite 3-O-methyl-[18F]fluoro-dopa on the relation between the 18F-fluorodopa tissue input uptake rate constant KOCC and the [18F]fluorodopa plasma input uptake rate constant Ki |
| 000971 |
Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Ali H. Rajput [Canada] ; Oleh Hornykiewicz [Canada, Autriche] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications |
| 000975 |
D. J. Brooks [Royaume-Uni] ; K. A. Frey [États-Unis] ; K. L. Marek [États-Unis] ; D. Cakes [États-Unis] ; D. Paty [Canada] ; R. Prentice [États-Unis] ; C. W. Shults [États-Unis] ; A. J. Stoessl [Canada] | Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease |
| 000979 |
C. Warren Olanow [États-Unis] ; Christopher G. Goetz [États-Unis] ; Jeffrey H. Kordower [États-Unis] ; A. Jon Stoessl [Canada] ; Vesna Sossi [Canada] ; Mitchell F. Brin [États-Unis] ; Kathleen M. Shannon [États-Unis] ; G. Michael Nauert [États-Unis] ; Daniel P. Perl [États-Unis] ; James Godbold [États-Unis] ; Thomas B. Freeman [États-Unis] | A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's Disease |
| 000992 |
T. A. Greenwood [États-Unis] ; M. Alexander [États-Unis] ; P. E. Keck [États-Unis] ; S. Mcelroy [États-Unis] ; A. D. Sadovnick [Canada] ; R. A. Remick [Canada] ; S. H. Jr Shaw [États-Unis] ; J. R. Kelsoe [États-Unis] | Segmental linkage disequilibrium within the dopamine transporter gene |
| 000993 |
Vincenzo Di Matteo [Italie] ; Marisa Cacchio [Italie] ; Camillo Di Giulio [Italie] ; Ennio Esposito [Italie] | Role of serotonin2C receptors in the control of brain dopaminergic function |
| 000A14 |
Vesna Sossi [Canada] ; Raul De La Fuente-Fernandez [Canada] ; James E. Holden [États-Unis] ; Doris J. Doudet [Canada] ; Jess Mckenzie [Canada] ; A. J. Stoessl [Canada] ; T. J. Ruth [Canada] | Increase in dopamine turnover occurs early in Parkinson's disease: Evidence from a new modeling approach to PET 18F-fluorodopa data |
| 000A27 |
G. A. Metz [Canada] ; I. Q. Whishaw [Canada] | Drug-induced rotation intensity in unilateral dopamine-depleted rats is not correlated with end point or qualitative measures of forelimb or hindlimb motor performance |
| 000A32 |
Ron Levy [Canada] ; Peter Ashby [Canada] ; William D. Hutchison [Canada] ; Anthony E. Lang [Canada] ; Andres M. Lozano [Canada] ; Jonathan O. Dostrovsky [Canada] | Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease |
| 000A47 |
Jean-Pierre Melun [Canada] ; Louise M. Morin [Canada] ; J. Gerard Muise [Canada] ; Marc Desrosiers [Canada] | Color vision deficiencies in Gilles de la Tourette syndrome |
| 000A80 |
Richard Camicioli [États-Unis, Canada] ; Eric Lea [États-Unis] ; John G. Nutt [États-Unis] ; Gary Sexton [États-Unis] ; Barry S. Oken [États-Unis] | Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: A pilot study |
| 000A87 |
M. Guttman [Canada] ; D. Stewart [Canada] ; D. Hussey [Canada] ; A. Wilson [Canada] ; S. Houle [Canada] ; S. Kish [Canada] | Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD |
| 000A91 |
Toshiya Murai [Canada, Allemagne] ; Ulrich Müller ; Katja Werheid ; Dietlind Sorger ; Mike Reuter ; Thomas Becker ; D. Yves Von Cramon ; Henryk Barthel | In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's Disease |
| 000B06 |
André Parent [Canada] ; Martine Cossette [Canada] | Extrastriatal dopamine and Parkinson's disease |
| 000B07 |
Raul De La Fuente-Fernandez [Canada] ; Thomas J. Ruth [Canada] ; Vesna Sossi [Canada] ; Michael Schulzer [Canada] ; Donald B. Calne [Canada] ; A. Jon Stoessl [Canada] | Expectation and dopamine release: Mechanism of the placebo effect in Parkinson's disease |
| 000B08 |
A. R. Zahran [Canada] ; N. Simmerman [Canada] ; S. Carrier [Canada] ; P. Vachon [Canada] ; Y. Sato | Erectile dysfunction occurs following substantia nigra lesions in the rat. Commentary |
| 000B10 |
Poornima K. Tekumalla [États-Unis] ; Frédéric Calon [Canada] ; Zia Rahman [États-Unis] ; Sam Birdi [Canada] ; Ali H. Rajput [Canada] ; Oleh Hornykiewicz [Canada, Autriche] ; Therese Di Paolo [Canada] ; Paul J. Bedard [Canada] ; Eric J. Nestler [États-Unis] | Elevated levels of ΔFosB and RGS9 in striatum in Parkinson's disease |
| 000B14 |
Jun-Xia Xie [République populaire de Chine] ; MING TANG [République populaire de Chine] ; CHUNYI ZHANG [Canada] | Effect of cholecystokinin-8 microinjection into ventral tegmental area on dopamine release in nucleus accumbens of rats: An in vivo voltammetric study |
| 000B16 |
Oleh Hornykiewicz [Autriche] | Dopamine and Parkinson's disease: A personal view of the past, the present, and the future |
| 000B20 |
Eric R. Marcotte [Canada] ; Anita Chugh [Canada] ; Cia Barlas [Canada] ; Ram K. Mishra [Canada] | Differential regulation of striatal G protein levels following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration in C57 BL/6 mice |
| 000B25 |
Hiroshi Ichinose [Japon] ; Takahiro Suzuki [Japon] ; Hidehito Inagaki [Japon] ; Tamae Ohye [Japon] ; Toshiharu Nagatsu [Japon] | DOPA-responsive dystonia: From causative gene to molecular mechanism |
| 000B32 |
Raul De La Fuente-Fernandez [Canada] ; Jian-Qiang Lu [Canada] ; Vesna Sossi [Canada] ; Salma Jivan [Canada] ; Michael Schulzer [Canada] ; James E. Holden [États-Unis] ; Chong S. Lee [Canada] ; Thomas J. Ruth [Canada] ; Donald B. Calne [Canada] ; A. Jon Stoessl [Canada] | Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease : PET evidence of increased dopamine turnover |
| 000B34 |
Raul De La Fuente-Fernandez [Canada] ; Andrew S. Lim [Canada] ; Vesna Sossi [Canada] ; James E. Holden [États-Unis] ; Donald B. Calne [Canada] ; Thomas J. Ruth [Canada] ; A. Jon Stoessl [Canada] | Apomorphine-induced changes in synaptic dopamine levels : Positron emission tomography evidence for presynaptic inhibition |
| 000B35 |
Lana Depatie [Canada] ; Samarthji Lal [Canada] | Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma? |
| 000B49 |
Hong Y. Choi [Canada] ; Jin H. Song [Canada] ; Dong K. Park [Corée du Sud] ; Gregory M. Ross [Canada] | The effects of ascorbic acid on dopamine-induced death of PC12 cells are dependent on exposure kinetics |
| 000B50 |
James N. Oak [Canada] ; John Oldenhof [Canada] ; Hubert H. M. Van Tol [Canada] | The dopamine D4 receptor : one decade of research |
| 000B77 |
A. M. Lozano [Canada] ; A. E. Lang [Canada] ; R. Levy [Canada] ; W. Hutchison [Canada] ; J. Dostrovsky [Canada] | Neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine |
| 000B92 |
R. De La Fuente-Fernandez [Canada] ; P. K. Pal [Canada] ; F. J. G. Vingerhoets [Canada] ; A. Kishore [Canada] ; M. Schulzer [Canada] ; E. K. Mak [Canada] ; T. J. Ruth [Canada] ; B. J. Snow [Canada] ; D. B. Calne [Canada] ; A. J. Stoessl [Canada] | Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations |
| 000C24 |
Juan Fernandez-Ruiz [États-Unis] ; Doris Doudet [Canada] ; Thomas G. Aigner [États-Unis] | Spatial memory improvement by levodopa in parkinsonian MPTP-treated monkeys |
| 000C32 |
Nicolaas Paul L. G. Verhoeff [Canada] | Radiotracer imaging of dopaminergic transmission in neuropsychiatric disorders |
| 000C46 |
H. M. Schipper [Canada] ; L. Bernier [Canada] ; K. Mehindate [Canada] ; D. Frankel [Canada] | Mitochondrial iron sequestration in dopamine-challenged astroglia : Role of heme oxygenase-1 and the permeability transition pore |
| 000C52 |
A. Richter [Allemagne] ; U. Ebert [Allemagne] ; J. N. Nobrega [Canada] ; J. J. Vallbacka [Canada] ; M. Fedrowitz [Allemagne] ; W. Löscher [Allemagne] | Immunohistochemical and neurochemical studies on nigral and striatal functions in the circling (ci) rat, a genetic animal model with spontaneous rotational behavior |
| 000C53 |
G. D. Muir [Canada] ; I. Q. Whishaw [Canada] | Ground reaction forces in locomoting hemi-parkinsonian rats : a definitive test for impairments and compensations |
| 000C54 |
M. Ichise [Canada] ; Y. J. Kim ; S. S. Erami ; J. R. Ballinger ; D. Vines ; F. Tanaka ; A. E. Lang | Functional morphometry of the striatum in Parkinson's disease on three-dimensional surface display of 123I-β-CIT SPECT data |
| 000C57 |
G. Flores [Mexique, Canada] ; J. J. Liang [Mexique, Canada] ; A. Sierra [Mexique] ; D. Martinez-Fong [Mexique] ; R. Quirion [Mexique, Canada] ; J. Aceves [Mexique] ; L. K. Srivastava [Mexique] | Expression of dopamine receptors in the subthalamic nucleus of the rat : Characterization using reverse transcriptase-polymerase chain reaction and autoradiography |
| 000C90 |
A. Samii [Canada] ; S. R. Letwin [Canada] ; D. B. Calne [Canada] | Prospects for new drug treatment in idiopathic parkinsonism |
| 000D10 |
E. G. Campioni [Canada] ; J. N. Nobrega [Canada] ; M. V. Sefton [Canada] | HEMA/MMMA microcapsule implants in hemiparkinsonian rat brain : Biocompatibility assessment using [3H]PK11195 as a marker for gliosis |
| 000D11 |
FENGQINSI [Canada] ; G. M. Ross [Canada] ; S. H. Shin [Canada] | Glutathione protects PC12 cells from ascorbate- and dopamine-induced apoptosis |
| 000D24 |
C. J. Gibson [Canada] ; D. G. Munoz [Canada] | Chromogranin A inhibits dopamine release from rat striatal slices |
| 000D28 |
D. A. Loeffler [États-Unis] ; P. A. Lewitt [États-Unis] ; P. L. Juneau [États-Unis] ; D. M. Camp [États-Unis] ; A. J. Demaggio [États-Unis] ; P. Milbury [États-Unis] ; W. R. Matson [États-Unis] ; M. P. Rathbone [Canada] | Altered guanosine and guanine concentrations in rabbit striatum following increased dopamine turnover |
| 000D48 |
M. Guttman [Canada] ; J. Burkholder [États-Unis] ; S. J. Kish [Canada] ; D. Hussey [États-Unis] ; A. Wilson [États-Unis] ; J. Dasilva [États-Unis] ; S. Houle [États-Unis] | [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease : Implications for the symptomatic threshold |
| 000D60 |
C.-T. Lai [Canada] ; P. H. Yu [Canada] | R(-)-deprenyl potentiates dopamine induced cytotoxicity toward catecholaminergic neuroblastoma SH-SY5Y cells |
| 000D91 |
C.-T. Lai [Canada] ; P. H. Yu [Canada] | Dopamine- and L-β-3,4-dihydroxyphenylalanine hydrochloride (L-Dopa)-induced cytotoxicity towards catecholaminergic neuroblastoma SH-SY5Y cells : effects of oxidative stress and antioxidative factors |
| 000E10 |
D. J. Martens [Canada] ; I. Q. Whishaw [Canada] ; E. I. Miklyaeva [Canada] ; S. M. Pellis [Canada] | Spatio-temporal impairments in limb and body movements during righting in an hemiparkinsonian rat analogue : relevance to axial apraxia in humans |
| 000E17 |
L. Wahl [Canada] ; C. Nahmias [Canada] | Modeling of fluorine-18-6-fluoro-L-Dopa in humans |
| 000E26 |
E. I. Miklyaeva [Canada] ; I. Q. Whishaw [Canada] | HemiParkinson analogue rats display active support in good limbs versus passive support in bad limbs on a skilled reaching task of variable height |
| 000E30 |
T. Roberts [Canada] ; U. De Boni ; M. V. Sefton [Canada] | Dopamine secretion by PC12 cells microencapsulated in a hydroxyethyl methacrylate-methyl methacrylate copolymer |
| 000E33 |
J. M. Wilson [Canada] ; A. I. Levey [États-Unis] ; A. Rajput [Canada] ; L. Ang [Canada] ; M. Guttman [Canada] ; K. Shannak [Canada] ; H. B. Niznik [Canada] ; O. Hornykiewicz [Canada, Autriche] ; C. Pifl [Autriche] ; S. J. Kish [Canada] | Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease |
| 000E44 |
M.-A. Bedard [Canada] ; M. Panisset | Neurochimie des troubles cognitifs dans la maladie de Parkinson |
| 000E48 |
J.-A. St-Pierre [Canada] ; P. J. Bedard | Systemic administration of the NMDA receptor antagonist MK-801 potentiates circling induced by intrastriatal microinjection of dopamine |
| 000E61 |
E. I. Miklyaeva [Canada] ; D. J. Martens ; I. Q. Whishaw | Impairments and compensatory adjustment in spontaneous movement after unilateral dopamine depletion in rats |
| 000E73 |
G. M. Ross [Canada] ; B. E. Mccarry ; R. K. Mishra [Canada] | Covalent affinity labeling of brain catecholamine-absorbing proteins using a high-specific-activity substituted tetrahydronaphthalene |
| 000E88 |
E. Scarr [Canada] ; D. M. Wingerchuk ; A. V. Juorio ; I. A. Paterson | The effects of monoamine oxidase B inhibition on dopamine metabolism in rats with nigro-striatal lesions |
| 000F03 |
K. Shannak [Canada] ; A. Rajput ; B. Rozdilsky ; S. Kish [Canada] ; J. Gilbert ; O. Hornykiewicz [Canada] | Noradrenaline, dopamine and serotonin levels and metabolism in the human hypothalamus : observations in Parkinson's disease and normal subjects |
| 000F12 |
A. H. Rajput [Canada] ; W. R. G. Gibb ; X. H. Zhong ; K. S. Shannak ; S. Kish ; L. G. Chang ; O. Hornykiewicz | Dopa-responsive dystonia : pathological and biochemical observations in a case |
| 000F22 |
A. Gjedde [Canada] ; G. C. Leger ; P. Cumming ; Y. Yasuhara ; A. C. Evans ; M. Guttman ; H. Kuwabara | Striatal L-DOPA decarboxylase activity in Parkinson's disease in vivo : implications for the regulation of dopamine synthesis |
| 000F39 |
B. J. Snow [Canada] ; I. Tooyama ; E. G. Mcgeer [Canada] ; T. Yamada ; D. B. Calne [Canada] ; H. Takahashi [Canada] ; H. Kimura | Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels |
| 000F46 |
B. D. Pate [Canada] ; T. Kawamata ; T. Yamada ; E. G. Mcgeer [Canada] ; K. A. Hewitt [Canada] ; B. J. Snow [Canada] ; T. J. Ruth [Canada] ; D. B. Calne [Canada] | Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices |
| 000F54 |
K. Mizukawa [Canada] ; E. G. Mcgeer ; P. L. Mcgeer | Autoradiographic study on dopamine uptake sites and their correlation with dopamine levels and their striata from patients with Parkinson disease, alzheimer disease, and neurologically normal controls |
| 000F64 |
D. B. Calne [Canada] | The nature of Pakinson's disease |
| 000F79 |
A. Tabatabaei [Canada] ; T. L. Perry ; S. Hansen ; C. Krieger | Partial protective effect of MK-4801 on MPTP-induced reduction of striatal dopamine in mice |
| 000F85 |
B. Lavoie [Canada] ; P.-Y. Cote ; A. Parent | Immunohistochemical study of the basal ganglia in normal and Parkinsonian monkeys |
| 000F97 |
M. L. Paul [Canada] ; A. M. Graybiel ; J.-C. David ; H. A. Robertson [Canada] | D1-like and D2-like dopamine receptors synergistically actitave rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease |
| 001007 |
S. J. Kish [Canada] ; K. Shannak ; A. Rajput ; J. H. N. Deck ; O. Hornykiewicz | Aging produces a specific pattern of striatal dopamine loss : implications for the etiology of idopathic Parkinson's disease |
| 001012 |
H. B. Niznik ; E. F. Fogel ; F. F. Fassos ; P. Seeman | The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus |
| 001026 |
F. B. Jolicoeur [Canada] ; R. Rivest ; A. Drumheller | Hypokinesia, rigidity, and tremor induced by hypothalamic 6-OHDA lesions in the rat |
| 001029 |
M. Filion ; L. Tremblay ; P. J. Bedard | Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism |
| 001051 |
B. J. Snow ; R. F. Peppard ; M. Guttman ; J. Okada ; W. Martin ; J. Steele ; A. Eisen ; G. Carr ; B. Schoenberg ; D. Calne | Positron emission tomographic scanning demonstrates a presynaptic dopaminergic lesion in lytico-bodig : the amyotrophic lateral sclerosis-Parkinsonism-dementia complex of guam |
| 001058 |
M. Guttman ; H. C. Fibiger ; A. Jakubovic ; D. B. Calne | Intracarotid 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration: biochemical and behavioral observations in a primate model of hemiparkinsonism |
| 001085 |
L. Tremblay ; M. Filion ; P. J. Bedard | Responses of pallidal neurons to striatal stimulation in monkeys with MPTP-induced parkinsonism |
| 001105 |
S. J. Kish ; K. Shannak ; O. Hornykiewicz | Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: pathophysiologic and clinical implications |
| 001108 |
T. L. Perry ; K. Jones ; S. Hansen | Tetrahydroisoquinoline lacks dopaminergic nigrostriatal neurotoxicity in mice |
| 001131 |
T. L. Perry ; K. Jones ; S. Hansen ; R. A. Wall | 2-Phenylpyridine and 3-phenylpyridine, constituents of tea, are unlikely to cause idiopathic Parkinson's disease |
| 001161 |
T. L. Perry ; K. Jones ; S. Hansen ; R. A. Wall | 4-phenylpyridine and three other analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lack dopaminergic nigrostriatal neurotoxicity in mice and marmosets |
| 001175 |
J. Kish ; A. Rajput ; J. Gilbert ; B. Rozdilsky ; L.-J. Chang ; K. Shannak ; O. Hornykiewicz | Elevated γ-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss |
